Syquant Capital

Form 8.3 - UDG LN

RNS Number : 8619H
Syquant Capital
06 August 2021
 

Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

Syquant Capital

Companydealtin

UDG Healthcare plc

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

EUR 0.05 ordinary shares

Date of dealing

August 5th, 2021

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 

 

(2) Derivatives (other than options)

10,681,272 (4.24%)

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

10,681,272 (4.24%)

 

             

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Classofrelevantsecurity:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit (Note 5)

 

 

 

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

(Note 5)

CFD

CFD

 

 

 

Increasing a long position

Increasing a long position

 

 

 

1,300,000

705,137

1077.50 GBp

1079.00 GBp

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing,   selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

 

(d)  Other   dealings   (including   transactions   in   respect   of   new   securities)   (Note   4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and 

any other person relating to the voting rights of any relevant securities under any option referred to 

on   this   form   or   relating   to   the   voting   rights   or   future   acquisition   or   disposal   of   any  relevant securities to 

which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    YES/NO

 

Dateofdisclosure

August 6th, 2021

Contact name

Alexandre Chevtchenko

Telephone number

+33 1 42 56 92 93

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

 

If aconnectedEFM,statenatureofconnection (Note 10)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEDKABQCBKKBFK